# IZABRIGHT-Bladder01: what clinicians are saying

> 16 statements from 8 sources (8 posts), 9 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
- NCT ID: NCT07106762
- Registry: https://clinicaltrials.gov/study/NCT07106762
- Sponsor: Bristol-Myers Squibb
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs tested: izalontamab brengitecan
- Indication: metastatic urothelial cancer with progression after immunotherapy
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: ef7f618cb97b794dcc2d7b323df6224f1972f9d6e0cc15c8ab9ba44be7421747

## Counts

- Commentary sources screened: 12
- Sources cited by verified statements: 8
- Verified statements: 16
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 9
- Findings: 5
- Named people in screened sources (unnamed speakers and accounts not counted): 5
- Speakers cited: 5
- Cited speakers with a verified identity: 5
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 4
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 4
- By role and specialty (the abstract's specialty counts):
  - 3 physician, specialty not confirmed
  - 1 physician, Medical oncology
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A physician supports the rationale for IZABRIGHT-Bladder01 amid another speaker’s description of unresolved treatment choices after EV/P. Direct trial commentary is limited; the broader sequencing context includes differing estimates of platinum activity, without enough study detail to reconcile them. These comments cannot establish the trial’s comparative benefit or safety.

## Question clinicians left open

What do clinicians need IZABRIGHT-Bladder01’s randomized comparison to establish about the activity of izalontamab brengitecan versus platinum before choosing second-line treatment after enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer?

From findings F1 (3 statements from 2 speakers in 1 source) and F2 (4 statements in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Iza-bren versus platinum: why a clinician supports the comparison
  - 3 statements from 2 speakers in 1 source.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 1 of the report's 4 cited clinicians.
- F2. Platinum after EV plus pembrolizumab: what speakers say
  - 4 statements in 2 sources.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F3. FGFR3/HER2: what speakers say
  - 2 statements from 1 speaker in 2 sources.
  - 1 of the report's 4 cited clinicians.
- F4. NECTIN4 after EV resistance: what a clinician asks about its validity
  - 4 statements from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 4 cited clinicians.
- F5. EV plus pembrolizumab resistance: why a clinician stresses trials and research access
  - 3 statements from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 4 cited clinicians.

3 of the 5 findings and 9 of the 16 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 3 | 2 | 1 | 2 | 3 |
| F2 | 4 | 2 | 2 | 0 | 4 |
| F3 | 2 | 2 | 2 | 1 | 2 |
| F4 | 4 | 1 | 1 | 1 | 2 |
| F5 | 3 | 3 | 3 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 2 | 0 | 0 | 0 | 1 | 3 | 0 | 1 post or article |
| F2 | 1 | 1 | 0 | 0 | 2 | 4 | 1 | 2 posts and articles |
| F3 | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 2 posts and articles |
| F4 | 3 | 1 | 0 | 0 | 0 | 4 | 0 | 1 post or article |
| F5 | 2 | 0 | 1 | 0 | 0 | 3 | 0 | 3 posts and articles |

### Trial dimensions

- Primary endpoint: Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507: no finding draws on it directly
- Primary endpoint: Phase 3: Progression-Free Survival (PFS): no finding draws on it directly
- Primary endpoint: Phase 3: Overall Survival (OS): no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (2 shared claims), F2 (1 shared claims)
- The comparison: F1 (3 shared claims), F2 (2 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F1 (1 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- HCP: healthcare professional
- HER2: human epidermal growth factor receptor 2
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- PFS: progression-free survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 16 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 8 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 4 of the 5 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

7 discussed · 5 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507 | no commentary found | 0 | 0 |
| Primary endpoint: Phase 3: Progression-Free Survival (PFS) | no commentary found | 0 | 0 |
| Primary endpoint: Phase 3: Overall Survival (OS) | no commentary found | 0 | 0 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 5 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 5 | 3 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 1 | 1 |
| External post-EV/P platinum estimates and fitness-dependent trial preference | discussed | 4 | 2 |
| Biomarker-directed alternatives and upfront testing | discussed | 2 | 2 |
| ADC switching, resistance biology and NECTIN4 uncertainty | discussed | 4 | 1 |
| Post-EV/P research priorities and referral access | discussed | 3 | 3 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Posts · 16 statements · 100%** | | | |
| X threads | 16 | 8 | 12 |

- Screened window: 2025-10-26 to 2026-11-17
- Cited window: 2025-10-26 to 2026-11-17
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
- Registry: NCT07106762 (https://clinicaltrials.gov/study/NCT07106762)
- Study IDs: CA244-0012 · EU CTR (2025-522400-24) · WHO (U1111-1322-9071)
- Sponsor: Bristol-Myers Squibb
- Design: Phase 2/Phase 3 · interventional, randomized, parallel, phase2, phase3
- Status: Recruiting
- Enrollment: 470 (estimated)
- Start: 2025-09-30 (actual)
- Primary completion: 2029-01-26 (estimated)
- Primary endpoint: Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507 (Approximately 3 months)
- Primary endpoint: Phase 3: Progression-Free Survival (PFS) (Up to 5 years)
- Primary endpoint: Phase 3: Overall Survival (OS) (Up to 5 years)
- Intervention: Iza-bren (drug)
- Intervention: Cisplatin (drug)
- Intervention: Gemcitabine (drug)
- Intervention: Carboplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on emerging treatment alternatives and targets for metastatic urothelial cancer after EVP; a question about additional treatment options after immunotherapy-based treatment in metastatic urothelial cancer.
- 26 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- The sources reviewed for this edition span October 2025–November 2026 and are limited to selected X discussions and summaries; their frequency does not measure how widely clinicians hold a view.
- Discussion using neither the trial identifier nor recognizable study or drug names, or using different acronyms, may be missing.
- No protocol or publication specific to NCT07106762 was identified in the reviewed material. Drug-label coverage was incomplete, and no exact Iza-bren label was identified; these discussions cannot establish a complete benefit–risk profile.
- The platinum estimates lack sufficient study and patient detail for direct comparison. Neither describes IZABRIGHT-Bladder01 arm outcomes.
- Two speakers relay attributed views; they are not additional clinician speakers. Reposts and quotations alone do not establish endorsement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- No reviewed statement appraises the trial’s dose selection, its PFS or OS endpoint performance, or comparative safety. Silence on these subjects is not reassurance.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 16 verified statements · 9 from 4 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (5 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/izabright-bladder01-nct07106762
- Agents: POST https://www.erudio.com/api/orders with {"report": "izabright-bladder01-nct07106762", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=izabright-bladder01-nct07106762

## Cite

Erudio Health. IZABRIGHT-Bladder01 (NCT07106762): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/izabright-bladder01-nct07106762

## Questions

### How much does the IZABRIGHT-Bladder01 report cost?

One edition costs $750 (Focused · 16 verified statements · 9 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the IZABRIGHT-Bladder01 report cover?

16 statements from 8 sources (8 posts), 9 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the IZABRIGHT-Bladder01 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "izabright-bladder01-nct07106762" }) previews it and create_order({ "report": "izabright-bladder01-nct07106762", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the IZABRIGHT-Bladder01 report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/izabright-bladder01-nct07106762.json
- Markdown: https://www.erudio.com/reports/izabright-bladder01-nct07106762.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/izabright-bladder01-nct07106762/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "izabright-bladder01-nct07106762"}`
